Search results
Results from the WOW.Com Content Network
On Tuesday, Danaher Corp (NYSE:DHR) reported third-quarter sales of $5.79 billion, up 3% year-over-year, beating the consensus of $5.59 billion. Guidance: Danaher reaffirms that in fiscal year ...
On Tuesday, Danaher Corp (NYSE:DHR) reported third-quarter sales of $5.79 billion, up 3% year-over-year, beating the consensus of $5.59 billion. Non-GAAP core revenue increased by 0.5%, compared ...
Danaher (DHR) delivered earnings and revenue surprises of 14.29% and 8.05%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Danaher Corporation (NYSE:DHR) shares are trading lower in the premarket session on Wednesday. The company reported fourth-quarter adjusted earnings per share of $2.14 missing the street view of ...
Danaher's (DHR) Q3 results reflect growth in Life Sciences and Diagnostics segments' sales, contribution from Cytiva, and operating margin rise. Core Q4 sales are likely to grow in high-single digits.
Danaher's (DHR) Q3 results are expected to reflect a healthy demand for products in Life Sciences and Diagnostics segments. Also, Cytiva is anticipated to have aided core sales.
Danaher (DHR) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Danaher (DHR) delivered earnings and revenue surprises of 0.87% and -0.06%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?